Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | RARB | P10826 | 3/20 | 0.46 |
| ▸ | RARG | P13631 | 3/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 7/20 | 0.43 |
| ▸ | RARA | P10276 | 2/20 | 0.43 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.43 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.43 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.43 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.42 |
| ▸ | PLA2G2D | Q9UNK4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL263313 | 1.00 | PTPN1 (0.59) | PTPN1KDM4ERARBRARGHSD11B1 | |
| SCHEMBL269488 | 0.86 | PTPN1 (0.43) | PTPN1HSD11B1 | |
| SCHEMBL264109 | 0.83 | CYP17A1 (0.50) | PTPN1KDM4EHSD11B1PDK1PDK2 | |
| SCHEMBL284052 | 0.83 | HSD11B1 (0.42) | PTPN1KDM4EHSD11B1 | |
| SCHEMBL30950643 | 0.83 | PTPN1 (0.57) | PTPN1KDM4ERARBRARGRARA | |
| SCHEMBL1842337 | 0.83 | PTPN1 (0.57) | PTPN1KDM4ERARBRARGRARA | |
| SCHEMBL2879876 | 0.83 | SRD5A2 (0.55) | RARBRARGHSD11B1SRD5A2 | |
| SCHEMBL1021804 | 0.83 | SRD5A2 (0.55) | RARBRARGHSD11B1SRD5A2 | |
| SCHEMBL263623 | 0.81 | PTPN1 (0.58) | PTPN1KDM4ERARBRARGRARA | |
| SCHEMBL1284827 | 0.81 | PTPN1 (0.68) | PTPN1KDM4ESRD5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7964732-B2 | Substituted bicyclocarboxyamide compounds | PFIZER INC. (US) | 2011-06-21 | — | — | US | disclosed |
| EP-2091944-B1 | SUBSTITUTED BICYCLOCARBOXYAMIDE COMPOUNDS | PFIZER (US) | 2011-05-18 | — | — | EP | disclosed |
| US-20100267769-A1 | Substituted Bicyclocarboxyamide Compounds | Pfizer, Inc. and Renovis Inc. | 2010-10-21 | — | — | US | disclosed |
| EP-2091944-A2 | SUBSTITUTED BICYCLOCARBOXYAMIDE COMPOUNDS | Pfizer, Inc. (US) | 2009-08-26 | — | — | EP | disclosed |
| WO-2008059370-A2 | SUBSTITUTED BICYCLOCARBOXYAMIDE COMPOUNDS | PFIZER JAPAN INC. (JP) | 2008-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267769-A1 | Substituted Bicyclocarboxyamide Compounds | TRPV1, OPRL1, CNR1 | PTPN1 3332/4885KDM4E 4164/4885RARB 1779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.